A proven approach

We believe Natera is well positioned to enter the early cancer diagnosis market. Natera’s technology, proven both clinically and commercially in the prenatal testing space, is expected to translate into the liquid biopsy space to help improve cancer diagnostics and the lives of patients.

A proven approach

We believe Natera is well positioned to enter the early cancer diagnosis market. Natera’s technology, proven both clinically and commercially in the prenatal testing space, is expected to translate into the liquid biopsy space to help improve cancer diagnostics and the lives of patients.

A proven approach

We believe Natera is well positioned to enter the early cancer diagnosis market. Natera’s technology, proven both clinically and commercially in the prenatal testing space, is expected to translate into the liquid biopsy space to help improve cancer diagnostics and the lives of patients.

A proven approach

We believe Natera is well positioned to enter the early cancer diagnosis market. Natera’s technology, proven both clinically and commercially in the prenatal testing space, is expected to translate into the liquid biopsy space to help improve cancer diagnostics and the lives of patients.

The American Cancer Society estimates there will be approximately 1.7 million new cancer cases diagnosed and more than 595,000 cancer deaths in the United States in 2016.

The American Cancer Society estimates there will be approximately 1.7 million new cancer cases diagnosed and more than 595,000 cancer deaths in the United States in 2016.

The American Cancer Society estimates there will be approximately 1.7 million new cancer cases diagnosed and more than 595,000 cancer deaths in the United States in 2016.

The American Cancer Society estimates there will be approximately 1.7 million new cancer cases diagnosed and more than 595,000 cancer deaths in the United States in 2016.

Potential applications

Cell-free DNA testing has the potential to revolutionize how we detect cancer. Natera's non-invasive testing method can assess the overall mutation load in patients with cancer using only a blood sample. This methodology may detect variants in plasma cell-free DNA that may not be detected by tissue biopsy. Natera’s testing method may also detect mutant DNA before a tumor is visible through medical imaging. Early detection is key to a positive prognosis.

 

Published Study

Potential applications

Cell-free DNA testing has the potential to revolutionize how we detect cancer. Natera's non-invasive testing method can assess the overall mutation load in patients with cancer using only a blood sample. This methodology may detect variants in plasma cell-free DNA that may not be detected by tissue biopsy. Natera’s testing method may also detect mutant DNA before a tumor is visible through medical imaging. Early detection is key to a positive prognosis.

 

Published Study

Potential applications

Cell-free DNA testing has the potential to revolutionize how we detect cancer. Natera's non-invasive testing method can assess the overall mutation load in patients with cancer using only a blood sample. This methodology may detect variants in plasma cell-free DNA that may not be detected by tissue biopsy. Natera’s testing method may also detect mutant DNA before a tumor is visible through medical imaging. Early detection is key to a positive prognosis.

 

Published Study

Potential applications

Cell-free DNA testing has the potential to revolutionize how we detect cancer. Natera's non-invasive testing method can assess the overall mutation load in patients with cancer using only a blood sample. This methodology may detect variants in plasma cell-free DNA that may not be detected by tissue biopsy. Natera’s testing method may also detect mutant DNA before a tumor is visible through medical imaging. Early detection is key to a positive prognosis.

 

Published Study

Partnering for success

Natera is working with world-renowned oncology centers on research collaborations, clinical trials and engaging with their leading doctors on our oncology advisory board. These institutions include:

  • Stanford University
  • Columbia University
  • Vanderbilt University
  • Cancer Research UK 

Partnering for success

Natera is working with world-renowned oncology centers on research collaborations, clinical trials and engaging with their leading doctors on our oncology advisory board. These institutions include:

  • Stanford University
  • Columbia University
  • Vanderbilt University
  • Cancer Research UK 

Partnering for success

Natera is working with world-renowned oncology centers on research collaborations, clinical trials and engaging with their leading doctors on our oncology advisory board. These institutions include:

  • Stanford University
  • Columbia University
  • Vanderbilt University
  • Cancer Research UK 

Partnering for success

Natera is working with world-renowned oncology centers on research collaborations, clinical trials and engaging with their leading doctors on our oncology advisory board. These institutions include:

  • Stanford University
  • Columbia University
  • Vanderbilt University
  • Cancer Research UK 
Back to Top